Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3557-3563

  Croisier Bertin, Delphine ^a   Piroth, Lionel ^a   Charles, Pierre Emmanuel ^a   Larribeau, Aurélie ^a   Biek, Donald ^b   Ge, Yigong ^b   Chavanet, Pascal ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; PENICILLIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; IN VIVO STUDY; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPLEEN; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PNEUMONIA, PNEUMOCOCCAL; RABBITS; STREPTOCOCCUS PNEUMONIAE;

EID: 79959236262     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01773-09     Document Type: Article

References (33)

1. Andes, D., and W. A. Craig. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
2. Appelbaum, P. C. 1996. Emerging resistance to antimicrobial agents in gram-positive bacteria. Drugs 51(Suppl. 1):S1-S5.
3. Azoulay-Dupuis, E., et al. 1991. Antipneumococcal activity of ciprofloxacin, ofloxacin and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J. Infect. Dis. 163:319-324.
4. Biek, D., Y. Ge, and D. F. Sahm. 2008. Activity of ceftaroline against common respiratory-associated pathogens from a collection of recent US isolates, poster C19. 2008 Am. Thor. Soc. Int. Conf., 16 to 21 May 2008, Toronto, Canada.
5. Centers for Disease Control and Prevention. 2007. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2006. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/abcs/reports-findings/survreports/spneu06.pdf.
6. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Comité de l'Antibiogramme de la Société Française de Microbiologie. 2008. Recommandations 2008, p. 38-40. Société Française de Microbiologie, Paris, France. http://www.sfm-microbiologie.org/UserFiles/file/CASFM/casfm-2008.pdf.
8. Croisier, D., et al. 2002. Pharmacodynamics (PKPD) of human-like treatment with moxifloxacin (MFX) and levofloxacin (LEV) on experimental pneumonia due to penicillin-resistant pneumococci (PRSP) with or without parC mutations. Presented at the 42nd Intersci. Conf. Antimicrob. Agents Chemother., 27 to 30 September 2002, San Diego, CA.
9. Croisier, D., et al. 2002. Value of the selection index (SI) and mutant selection window (MSW) in the pharmacodynamics (PKPD) of mutants (M): application to fluoroquinolones versus pneumococcal pneumonia (PP). Presented at the 42nd Intersci. Conf. Antimicrob. Agents Chemother., 27 to 30 September 2002, San Diego, CA.
10. Croisier, D., et al. 2002. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J. Antimicrob. Chemother. 50:349-360.
11. Croisier, D., et al. 2004. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J. Antimicrob. Chemother. 54:640-647.
12. Davidson, R., et al. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
13. Draghi, D. C., et al. 2006. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004). Int. J. Antimicrob. Agents 28:525-531. (Pubitemid 44781409)
14. Empey, P. E., et al. 2001. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann. Pharmacother. 35:687-690.
15. Etienne, M., et al. 2004. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits. J. Infect. Dis. 190:1472-1475.
16. Felmingham, D., et al. 2005. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 56(Suppl. 2):ii3-ii21.
17. Fishman, N. O., et al. 1999. Three levofloxacin treatment failures of pneumococcal respiratory tract infections. Presented at the 39th Intersci. Conf. Antimicrob. Agents Chemother., 26 to 29 September 1999, San Francisco, CA.
18. Ge, Y., et al. 2007. In vitro activity of ceftaroline against a collection of recent gram-positive and gram-negative US isolates. Presented at the 47th Intersci. Conf. Antimicrob. Agents Chemother., 17 to 20 September 2007, Chicago, IL.
19. Ge, Y., et al. 2006. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (IV) infusions. Presented at the 46th Intersci. Conf. Antimicrob. Agents Chemother., 17 to 20 September 2006, San Francisco, CA.
20. Goonetilleke, A. K., et al. 1996. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. J. Antimicrob. Chemother. 38:969-976.
21. Jacobs, M. R., et al. 2008. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 46:982-990.
22. Jacqueline, C., et al. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400.
23. Leggett, J. E., et al. 1990. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis model. Scand. J. Infect. Dis. Suppl. 74:179-184.
24. Meyers, B. R., et al. 1983. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob. Agents Chemother. 24:812-814.
25. Morrissey, L., et al. 2007. Activity of ceftaroline against community-acquired pneumonia (CAP) bloodstream isolates. Presented at the 47th Intersci. Conf. Antimicrob. Agents Chemother., 17 to 20 September 2007, Chicago, IL.
26. Mushtaq, S., M. Warner, Y. Ge, K. Kaniga, and D. M. Livermore. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60:300-311.
27. Piroth, L., et al. 1999. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob. Agents Chemother. 43:2484-2492.
28. Sader, H. S., T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1153-1155.
29. Sader, H. S., et al. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512.
30. Société de Pathologie Infectieuse de Langue Française. 2000. Révision de la IVe conférence de consensus en thérapeutique anti-infectieuse de la Société de Pathologie Infectieuse de Langue Française. Méd. Mal. Infect. 30:566-580.
31. Song, J. H., et al. 2008. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int. J. Antimicrob. Agents 31:107-114.
32. Wortmann, G. W., and S. P. Bennett. 1999. Fatal meningitis due to levo-floxacin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 29:1599-1600.
33. Zervos, M., et al. 2004. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with stepdown oral therapy for hospitalized patients with moderate to severe community acquired pneumonia. Treat. Respir. Med. 3:329-336.